My team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure.
Dr. Ravi Thadhani
Dr. Thadhani trained at the Massachusetts General Hospital, Harvard Medical School, where he has been since 1991. He was a Fellow in Nephrology between the years 1994-1998 and currently serves as the Director of Clinical Research in Nephrology. He has two major interests, preeclampsia and dialysis mortality. He has published 100+ manuscripts in these and related areas. His focus is to bring novel therapies and diagnostics to patients with renal failure in hopes to improve outcomes. He is currently working on therapeutic strategies to alleviate the signs and symptoms of preeclampsia. He is also focused on the cardiovascular and infectious consequences of defective vitamin D signaling in subjects with renal failure. His team has performed several hypothesis-generating observational studies suggesting that therapy with activated vitamin D sterols is associated with improved survival among patients with renal failure. In addition, he has carried out a series of in-vivo studies in rodents which suggests that activated vitamin D sterols prevent the progression of cardiac hypertrophy and heart failure via inhibition of renin-angiotensin pathway and other pathways. Based on these observational human studies and in-vivo rodent experiments, he has initiated a multicenter randomized trial to test our hypothesis in humans.